Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns

Circulation. Heart Failure
João Pedro FerreiraFaiez Zannad

Abstract

Patients with heart failure with reduced ejection fraction have a poor prognosis. The identification of subgroups with different outcomes and treatment response patterns may help to tailor strategies to each individual patient. We present an exploratory study of patients enrolled in the EMPHASIS-HF trial (Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms) using latent class analysis with validation using the EPHESUS trial (Eplerenone, a Selective Aldosterone Blocker, in Patients With Left Ventricular Dysfunction After Myocardial Infarction) to identify subgroups of patients with different prognosis and response to eplerenone therapy. Latent class analysis identifies mutually exclusive groups of individuals maximizing within-group similarities and between-group differences. In the EMPHASIS-HF trial, 2279 heart failure with reduced ejection fraction patients were randomized to eplerenone or placebo and were characterized according to 18 clinical features. Subgroup definitions were applied to 6472 patients enrolled in the EPHESUS trial to validate observations. Event-free survival and effect of eplerenone on the composite of cardiovascular death and heart failure hospitalization were determined for each subgroup...Continue Reading

References

Sep 19, 2006·Journal of the American College of Cardiology·Aidan P BolgerCallum M Chapman
Nov 13, 2008·Circulation·Pardeep S Jhund, John J V McMurray
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Oct 22, 2009·JAMA : the Journal of the American Medical Association·Nancy M AlbertGregg C Fonarow
Nov 19, 2009·The New England Journal of Medicine·Stefan D AnkerUNKNOWN FAIR-HF Trial Investigators
Nov 16, 2010·The New England Journal of Medicine·Faiez ZannadUNKNOWN EMPHASIS-HF Study Group
Dec 15, 2010·Journal of the American College of Cardiology·Jalal K GhaliMichael W Rich
Feb 15, 2011·Prevention Science : the Official Journal of the Society for Prevention Research·Stephanie T Lanza, Brittany L Rhoades
Jun 7, 2011·American Heart Journal·Gregg C FonarowPaul A Heidenreich
Dec 6, 2011·Pharmaceutical Statistics·Marie-Ange PagetCarol Reid
May 9, 2014·Circulation. Heart Failure·Orly VardenyUNKNOWN Randomized Aldactone Evaluation Study (RALES) Investigators
Nov 22, 2014·The New England Journal of Medicine·Matthew R WeirUNKNOWN OPAL-HK Investigators
Dec 3, 2014·Journal of the American College of Cardiology·Tariq AhmadG Michael Felker
Dec 3, 2014·Journal of the American College of Cardiology·Robert J MentzChristopher M O'Connor
Dec 4, 2014·International Journal of Cardiology·Patrick RossignolUNKNOWN Writing group of 10th Global Cardio Vascular Clinical Trialist forum held on December 6th-7th 2013 in Paris, France
Feb 11, 2015·The Canadian Journal of Cardiology·Pritha P GuptaTamara B Horwich
Sep 26, 2015·Seminars in Hematology·M Domenica Cappellini, Irene Motta
Nov 10, 2015·JAMA : the Journal of the American Medical Association·Lauren B CooperAdrian F Hernandez
Jul 30, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Bertram Pitt, Patrick Rossignol
Nov 22, 2016·European Journal of Heart Failure·Patrick RossignolBertram Pitt
Jul 14, 2017·Circulation·Dirk J van VeldhuisenUNKNOWN EFFECT-HF Investigators

❮ Previous
Next ❯

Citations

Jul 13, 2018·Circulation. Heart Failure·Julio A Chirinos, David E Lanfear
Mar 4, 2019·Current Hypertension Reports·Antonis A ManolisAntonis S Manolis
Feb 18, 2021·Diabetologia·Wolfgang Rathmann, Brenda Bongaerts
Feb 20, 2021·Scientific Reports·Gregoire Preud'hommeNicolas Girerd
Jul 23, 2020·Acta Pharmaceutica : a Quarterly Journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, Dealing with All Branches of Pharmacy and Allied Sciences·Qianqian LiShaofeng Rong
Aug 8, 2021·ESC Heart Failure·Farnaz NamaziJeroen J Bax

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.